---
document_datetime: 2023-09-21 20:03:06
document_pages: 16
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/fertavid-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: fertavid-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 9.1527223
conversion_datetime: 2025-12-28 12:21:41.859767
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Fertavid

Procedural steps taken and scientific information after the authorisation

<!-- image -->

| Application number   | Scope                                                                                                                                                                                                                                                                                           | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on no   | Product Information affected 3   | Summary                                                                                                                                                                                                                |
|----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|------------------------------------------------|----------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WS/1702              | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Update of section 4.4 of the SmPC in order to revise the safety information regarding Ovarian Hyperstimulation Syndrome (OHSS) to replace product | 28/11/2019                          | 20/01/2020                                     | SmPC, Labelling and PL           | Section 4.4 of the SmPC containing information on the special warnings and precautions for use was updated as per current knowledge in relation to the safety information regarding Ovarian Hyperstimulation Syndrome. |

<!-- image -->

Medicinal product no longer authorised

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | the recommendation practice for reducing the risk of OHSS during Assisted Reproductive Technology (ART), based on post-marketing data and literature review. The package Leaflet is updated accordingly. In addition, the worksharing applicant (WSA) took the opportunity to update the list of local representatives in the Package Leaflet and made some editorial changes in the Product Information. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data   | to follow current clinical longer authorised   |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------|
| IB/0045   | B.II.z - Quality change - Finished product - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 25/07/2019 n/a no                              |
| WS/1502   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal product and is not related to a protocol product                                                                                                              | 16/05/2019 n/a                                 |
| IG/1062   | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 11/02/2019 n/a                                 |
| WS/1457/G | This was an application for a group of variations following a worksharing procedure according to                                                                                                                                                                                                                                                                                                                                                                                                                              | 13/12/2018 n/a                                 |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | Article 20 of Commission Regulation (EC) No 1234/2008. B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate                                                                                                                          | longer authorised                     |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------|
| IG/0968   | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 28/09/2018 16/09/2019 Annex II and PL |
| WS/1339/G | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a biological AS B.III.2.z - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Other variation product | 12/07/2018 n/a no                     |
| T/0039    | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 13/06/2018 06/07/2018 SmPC,           |

<div style=\"page-break-after: always\"></div>

|                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |            |        | PL                                |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|--------|-----------------------------------|
| PSUSA/1465/ 201705 | Periodic Safety Update EU Single assessment - follitropin beta                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 30/11/2017 | n/a    | PRAC Recommendation - maintenance |
| WS/1186/G          | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a biological AS B.II.d.2.c - Change in test procedure for the finished product - Substantial change to or replacement of a biol/immunol/immunochemical test method or a method using a biol. reagent or replacement of a biol. reference preparation not covered by an approved protocol product | 13/07/2017 | n/a no | longer authorised                 |
| WS/1124            | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.a.4.e - Change to in-process tests or limits applied during the manufacture of the AS - Deletion of an in-process test which may have a significant effect on the overall quality of the AS                                                                                                                                                                                                                                                                                                                                             | 21/04/2017 | n/a    |                                   |

<div style=\"page-break-after: always\"></div>

| N/0035    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 08/03/2017   | 28/04/2017   | Labelling   |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|-------------|
| IG/0762   | B.II.e.2.a - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Tightening of specification limits                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 26/01/2017   | n/a          | authorised  |
| IG/0730   | B.II.e.6.b - Change in any part of the (primary) packaging material not in contact with the finished product formulation - Change that does not affect the product information                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 10/10/2016   | n/a          |             |
| WS/0975/G | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a biological AS B.II.d.2.c - Change in test procedure for the finished product - Substantial change to or replacement of a biol/immunol/immunochemical test method or a method using a biol. reagent or replacement of a biol. reference preparation not covered by an approved protocol product | 15/09/2016   | n/a no       | longer      |
| IG/0703/G | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 18/07/2016   | n/a          |             |

<div style=\"page-break-after: always\"></div>

|           | B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                                                                                                                                                      |            |                                                 |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-------------------------------------------------|
| IB/0029   | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 23/05/2016 | 28/04/2017 SmPC, Annex II, Labelling authorised |
| IG/0545/G | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.II.e.3.a - Change in test procedure for the immediate packaging of the finished product - Minor changes to an approved test procedure B.II.e.6.b - Change in any part of the (primary) packaging material not in contact with the finished product formulation - Change that does not affect the product information product | 27/04/2015 | and PL n/a no longer                            |
| WS/0691   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other                                                                                                                                                                                                                                                                                                                                                                       | 26/03/2015 | n/a                                             |

<div style=\"page-break-after: always\"></div>

|           | variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |            |                      |                                          |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|----------------------|------------------------------------------|
| PSUV/0024 | Periodic Safety Update                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 04/12/2014 | n/a                  | PRAC Recommendation - maintenance        |
| WS/0627   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Addition of a site where batch control/testing takes place for the finished product B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place                                                                   | 20/11/2014 | n/a                  | authorised                               |
| N/0026    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                               | 18/11/2014 | 19/02/2015 no longer |                                          |
| WS/0571/G | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Changes in the test procedure of the AS. B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a product | 25/09/2014 | n/a                  | Changes in the test procedure of the AS. |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | biological/immunological/immunochemical test method or a method using a biological reagent for a biological AS B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |            |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|
| IG/0449/G | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.III.1.b.3 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - Updated certificate from an already approved manufacturer B.III.1.b.3 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - Updated certificate from an already approved manufacturer product no | 29/07/2014 |
| WS/0487/G | This was an application for a group of variations following a worksharing procedure according to                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 20/03/2014 |

<div style=\"page-break-after: always\"></div>

<!-- image -->

<div style=\"page-break-after: always\"></div>

|         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |            |               |                                  | During the reporting period of Fertavid renewal (2 May 2011 - 6 June 2013) no new clinical data became available which would impact the benefit-risk profile. Therefore the CHMP considers that risk benefit profile remains positive and the renewal can be granted with unlimited validity. authorised                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|---------------|----------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WS/0465 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Update of Product Information (PI) to address common medical knowledge concerning assisted reproduction technology regarding : monitoring of ovarian response (SmPC section 4.2) ; updates regarding infertility evaluation before starting treatment, multiple pregnancy, ectopic pregnancy, ovarian hyperstimulation syndrome, ovarian torsion, ovarian and other reproductive system neoplasms, vascular complications, other medical conditions (SmPC section 4.4). The Package leaflet is updated accordingly. The MAH is taking the opportunity to update the PI in line with QRD template version 9 and to make other editorial corrections. In addition, the details of the local representative of Croatia have been included in the German, Greek, Spanish and Italian PL. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data product | 20/02/2014 | 19/02/2015 no | SmPC, Annex II, Labelling and PL | The Company has updated the product information, and has referred to published literature and the QRD template to justify changes in the wording of sections 4.2, 4.4 and 4.6 of the SmPC. The Company has revised wording of section 4.2 and 4.4 of the SPC to reflect current clinical practice in the management of fertility that recommends use of ultrasound images to guide management with the medicinal product by following follicular development and by detecting multi-fetal gestations. The Company has introduced information to section 4.4 of the SmPC on management of the ovarian hyper-stimulation syndrome. The revised wording is acceptable and is considered to enhance clinical safety of patients. Grammatical changes have been made to sections 4.4, 4.6, 4.8 and 5 of the SmPC to improve clarity of meaning on use of the medicinal product and to comply with the QRD template; furthermore minor editorial corrections were made throughout the SmPC. These changes are also acceptable. The PL has been updated in order to reflect the SmPC changes described above. Overall, the changes to the product information texts are considered to improve clinical safety and so the benefit / risk balance of the current product in the stated indications remains as positive. longer |

<div style=\"page-break-after: always\"></div>

| IA/0020/G   | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of                                                                                                                                                                                                                                                                                                                                                                          | 13/12/2013   | 21/02/2014   | Annex II and PL   |
|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|-------------------|
| IG/0366     | manufacturing sites C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location                                                                                                                                                                                                                                                                                                                                                 | 08/11/2013   | n/a          | authorised        |
| N/0016      | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                    | 28/10/2013   | 21/02/2014   | PL longer         |
| IG/0184     | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                      | 21/08/2012   | n/a no       |                   |
| WS/0228/G   | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Change to the control of the active substance B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Change (replacement) to a biological/immunological/ immunochemical test method or a method using a biological reagent for a biological AS B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting product | 19/04/2012   | n/a          |                   |

<div style=\"page-break-after: always\"></div>

|           | material/intermediate/reagent - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0013/G | This was an application for a group of variations. A.5.b - Administrative change - Change in the name and/or address of a manufacturer of the finished product, including quality control sites (excluding manufacturer for batch release) A.7 - Administrative change - Deletion of manufacturing sites B.III.1.b.3 - Submission of a new or updated Ph. Eur. TSE Certificate of suitability - Updated certificate from an already approved manufacturer B.III.1.b.3 - Submission of a new or updated Ph. Eur. 22/12/2011 21/02/2012 SmPC, Annex II, Labelling and PL longer authorised                                             |
| IG/0117/G | TSE Certificate of suitability - Updated certificate from an already approved manufacturer This was an application for a group of variations. C.I.9.c - Changes to an existing pharmacovigilance system as described in the DDPS - Change of the back-up procedure of the QPPV C.I.9.g - Changes to an existing pharmacovigilance system as described in the DDPS - Change of the site undertaking pharmacovigilance activities C.I.9.a - Changes to an existing pharmacovigilance system as described in the DDPS - Change in the QPPV C.I.9.h - Changes to an existing pharmacovigilance 18/11/2011 18/11/2011 Annex II product no |

<div style=\"page-break-after: always\"></div>

| T/0007    | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 22/07/2011   | 26/08/2011    | SmPC, Labelling and PL   | Transfer of Marketing Authorisation from Shering-Plough Europe to Merck, Sharp & Dohme Ltd.   |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|---------------|--------------------------|-----------------------------------------------------------------------------------------------|
| WS/0112   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Changes to the manufacturing process of the drug product B.II.b.3.c - Change in the manufacturing process of the finished product - The product is a biological/immunological medicinal product and the                                                                                                                                                                         | 17/03/2011   | 17/03/2011    | longer                   | authorised                                                                                    |
| WS/0072/G | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Changes to the active substance manufacturing process and control. B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation product | 17/03/2011   | 17/03/2011 no |                          |                                                                                               |

<div style=\"page-break-after: always\"></div>

|         | B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological medicinal product and is not related to a protocol                                                                                                |                    |               |                        | authorised                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|---------------|------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WS/0034 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre- clinical, clinical or pharmacovigilance data | 21/10/2010 product | 29/11/2010 no | SmPC, Labelling and PL | This type II variation concerns a safety update of the SPC following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Following a re-analysis of safety data a separate warning regarding ovarian torsion is included in the SPC Section 4.4. OHSS, pregnancy, previous abdominal surgery, past history of ovarian torsion, previous or current ovarian cyst and polycystic ovaries have been identified as risk factors for ovarian torsion. Damage to the ovary due to reduced blood supply can be limited by early diagnosis and immediate detorsion. SPC Section 4.8 was amended by including the following adverse reactions in the table concerning treatment in females: abdominal discomfort, constipation, diarrhoea, metrorrhagia, ovarian cyst, ovarian torsion, uterine enlargement, vaginal haemorrhage (uncommon). Headache, rash and injection site pain (common) are included in the table concerning treatment in men. Minor changes in the labelling and other SPC sections (4.1; 4.2; 4.3; 4.6) and corrections of linguistic differences between the Puregon and Fertavid texts were also agreed. The PL is updated accordingly. longer |
| WS/0033 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.                                                                                                                                                        | 23/09/2010         | 28/10/2010    | SmPC                   | Section 5.1 of the SmPC was amended to support the current information in Section 4.2. The information added to SmPC 5.1 shows a comparison to urinary FSH, including presentation of study data on (mean) total dosage and                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |

<!-- image -->

<div style=\"page-break-after: always\"></div>

|         | C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre- clinical, clinical or pharmacovigilance data                                                      |            |               |                        | treatment period needed. A minor change was also made to the text of SmPC section 4.2.                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|---------------|------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0006 | Update of Summary of Product Characteristics, Labelling and Package Leaflet                                                                                                                                 | 22/04/2010 | 02/06/2010    | SmPC, Labelling and PL | The Fertavid Product Information was updated (in line with recent Puregon updated text) to comply with the SPC guideline and QRD template by using short terms for the pharmaceutical form in section 3 of the SPC and in section 6 of the Package Leaflet, by using abbreviated terms for the administration route in the Labelling as well as by harmonising the prefixes used in the Labelling. Also the Package Leaflet has been updated following the conduct of a Readability Testing on the vials Package Leaflet. longer authorised |
| II/0004 | Update of the Detailed Description of the Pharmacovigilance System (DDPS) including change of the Qualified Person for Pharmacovigilance (QPPV). Changes to QPPV Update of DDPS (Pharmacovigilance) product | 20/01/2010 | 11/02/2010 no | Annex II               | The DDPS has been updated to reflect the change of the QPPV as well as to notify other changes to the DDPS performed since the last approved version. Consequently, Annex II has been updated including the new version number (version 7) of the agreed DDPS. The CHMP considers that the Pharmacovigilance System as described by the MAH is acceptable.                                                                                                                                                                                  |
| II/0005 | Change to the purification process of the drug substance. Change(s) to the manufacturing process for the active substance                                                                                   | 19/11/2009 | 19/11/2009    |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| II/0001 | Changes to control of the active substance Change(s) to the test method(s) and/or specifications for the active substance                                                                                   | 24/09/2009 | 05/10/2009    |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |

<div style=\"page-break-after: always\"></div>

| IB/0002   | IB_38_b_Change in test procedure of finished product - minor change, biol. active subst./excipient   | 04/08/2009   | n/a   |                 |
|-----------|------------------------------------------------------------------------------------------------------|--------------|-------|-----------------|
| IA/0003   | IA_05_Change in the name and/or address of a manufacturer of the finished product                    | 20/07/2009   | n/a   | Annex II and PL |

<!-- image -->